Recludix Pharma secured IND clearance from the FDA to advance REX‑8756 (SAR‑448755), an oral STAT6 inhibitor, into first‑in‑human phase I testing for inflammatory diseases. The small‑molecule program targets STAT6’s SH2 domain and represents a non‑canonical approach to type‑2 inflammation and fibrotic disorders. Separately, Nchroma Bio received Hong Kong clearance to initiate a phase I/II trial of CRMA‑1001 for chronic hepatitis B, with dosing expected early next year. Both regulatory green lights add to a busy wave of early‑stage immunology and antiviral clinical starts that could feed mid‑stage pipelines over the next two years.